Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 11/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23943298 | 0.71 | MAPT (0.42) | MAPTGSK3BCYP26A1HTR6 | |
| SCHEMBL21683128 | 0.69 | HRH3 (0.53) | MAPTGSK3BHDAC8CTSD | |
| SCHEMBL21683131 | 0.69 | HRH3 (0.53) | MAPTGSK3BHDAC8CTSD | |
| SCHEMBL23943299 | 0.67 | — | — | |
| SCHEMBL11926046 | 0.65 | MAPT (0.53) | MAPTGSK3BTBXA2RHDAC8CYP26A1 | |
| SCHEMBL16701655 | 0.65 | CYP19A1 (0.44) | MAPT | |
| SCHEMBL4183536 | 0.64 | MAPT (0.47) | MAPTGSK3BCYP26A1HTR6 | |
| SCHEMBL76518 | 0.62 | CTSD (0.45) | MAPTGSK3BCYP26A1CTSDHTR6 | |
| SCHEMBL11476670 | 0.62 | CTSD (0.45) | MAPTGSK3BCYP26A1CTSDHTR6 | |
| SCHEMBL9015434 | 0.62 | GSK3B (0.50) | MAPTGSK3BTBXA2RCYP26A1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | MAPT 3234/4885GSK3B 556/4885TBXA2R 933/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | MAPT 3234/4885GSK3B 556/4885TBXA2R 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.